Changes

no edit summary
Line 1,252: Line 1,252:  
| ||
 
| ||
 
|-
 
|-
|T-prolymphocytic leukaemia||Disease|| || || || || ||SK||
+
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD||
 
| ||
 
| ||
 +
|-
 +
|Early T-precursor lymphoblastic leukaemia / lymphoma
 +
|Disease
 +
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|
 +
|-
 +
|T-prolymphocytic leukaemia
 +
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|SK
 +
|
 +
|
 +
|
 
|-
 
|-
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK||
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK||
Line 1,477: Line 1,501:  
|
 
|
 
|
 
|
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
| || || || || || || || ||
  −
| ||
  −
|-
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma||Disease|| || || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy||Disease||Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG|| || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with iAMP21||Disease||Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte|| || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features||Disease||Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine|| || || || ||YA||
  −
| ||
  −
|-
  −
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement||Disease||Yassmine Akkari  Nicolas Millan|| || || || ||YA||
  −
| ||
  −
|-
  −
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion||Disease||Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma|| || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features||Disease|| || || || || ||YA||
  −
| ||
  −
|-
  −
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
  −
| ||
  −
|-
  −
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
  −
| ||
  −
|-
  −
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion||Disease|| || || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations||Disease|| || || || || ||YA||
  −
| ||
  −
|-
  −
|B-lymphoblastic leukaemia/lymphoma, NOS||Disease|| || || || || ||YA||
  −
| ||
  −
|-
  −
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||YA||
  −
| ||
  −
|-
  −
|Early T-precursor lymphoblastic leukaemia / lymphoma||Disease||Fei Yang, MD, FACMG, Kaiser Permanente Northwest|| || || || ||YA||
  −
| ||
   
|-
 
|-
 
|Fanconi anaemia||Disease|| || || || || ||NA||
 
|Fanconi anaemia||Disease|| || || || || ||NA||